Market capitalization | $4.52b |
Enterprise Value | $4.05b |
P/E (TTM) P/E ratio | 38.39 |
EV/FCF (TTM) EV/FCF | 32.89 |
EV/Sales (TTM) EV/Sales | 7.12 |
P/S ratio (TTM) P/S ratio | 7.94 |
P/B ratio (TTM) P/B ratio | 7.58 |
Revenue growth (TTM) Revenue growth | 33.04% |
Revenue (TTM) Revenue | $569.61m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
5 Analysts have issued a Corcept Therapeutics Incorporated. forecast:
5 Analysts have issued a Corcept Therapeutics Incorporated. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 570 570 |
33%
33%
|
|
Gross Profit | 561 561 |
33%
33%
|
|
EBITDA | 129 129 |
27%
27%
|
EBIT (Operating Income) EBIT | 128 128 |
29%
29%
|
Net Profit | 125 125 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Joseph Belanoff |
Employees | 352 |
Founded | 1998 |
Website | www.corcept.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.